Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
477.37
+5.37 (+1.14%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vertex Pharmaceuticals
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
51
52
Next >
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
December 27, 2023
With a new medicine on the market and plenty of money, Vertex is in great shape.
Via
The Motley Fool
3 Monster Stocks to Buy Without Any Hesitation
December 27, 2023
These are easy choices for investors seeking market-beating long-term gains.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
December 25, 2023
Via
Benzinga
3 Top Stocks to Buy Hand Over Fist Before the End of 2023
December 25, 2023
These are ideal stocks to buy sooner rather than later.
Via
The Motley Fool
Editas Just Caught a Break Thanks to Vertex Pharmaceuticals
December 23, 2023
Editas isn't out of the woods yet, but it's better off than before.
Via
The Motley Fool
1 Green Flag and 1 Red Flag for Bluebird Bio Stock
December 23, 2023
The stock has been in the news lately.
Via
The Motley Fool
Market Whales and Their Recent Bets on VRTX Options
December 22, 2023
Via
Benzinga
How Is The Market Feeling About Vertex Pharmaceuticals?
December 21, 2023
Via
Benzinga
$1000 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
December 19, 2023
Via
Benzinga
5 Top Stocks to Buy With Your End-of-the-Year Bonus
December 23, 2023
Your bonus could become the gift that keeps on giving.
Via
The Motley Fool
Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?
December 22, 2023
Both develop medicines for rare diseases, and each aims to conquer a niche market.
Via
The Motley Fool
Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock?
December 22, 2023
The FDA's recent approval of CRISPR Therapeutics' first therapy is a step in the right direction.
Via
The Motley Fool
Exposures
Product Safety
3 Biotech Stocks to Buy in the TradeSmith ‘Green Zone’
December 21, 2023
It's now time to take a look at these three biotech stocks to buy, as each one is currently within TradeSmith's "Green Zone."
Via
InvestorPlace
Should you consider NASDAQ:VRTX for quality investing?
December 21, 2023
Reasonable Growth, Debt Levels, and a High ROIC Make VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) Appealing to Quality Investors.
Via
Chartmill
Is Vertex Pharmaceuticals Sitting on a Gold Mine?
December 21, 2023
Vertex shares have climbed about 40% this year.
Via
The Motley Fool
After This Landmark Win, Is CRISPR Therapeutics a Buy?
December 15, 2023
CRISPR Therapeutics stock already has advanced in the double digits this year.
Via
The Motley Fool
Why Vertex Stock Is Soaring Today
December 13, 2023
The drugmaker's non-opioid painkiller is showing promise in a select set of patients.
Via
The Motley Fool
CRSP Stock Alert: CRISPR Therapeutics Is Losing Its Medical Chief
December 20, 2023
The fate of Crispr and CRSP stock will be determined by the success of other drugs in the company's pipeline rather than Casgevy.
Via
InvestorPlace
Better Growth Stock: Archer Aviation or Prime Medicine?
December 19, 2023
Which of these innovation-themed growth stocks is the better buy?
Via
The Motley Fool
Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
December 18, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
2 Stocks Profiting From Unstoppable Trends That Could Make You Rich
December 18, 2023
It's important to choose companies involved in trends that have long-term potential.
Via
The Motley Fool
CRISPR Therapeutics Just Made History. So Why Did Its Stock Fall?
December 16, 2023
The benefits from its first drug launch will trickle in slowly, at least at first.
Via
The Motley Fool
Here's the 1 Key Reason You Might Want to Buy CRISPR Therapeutics Stock on the Dip
December 16, 2023
This biotech could have more winners on the way.
Via
The Motley Fool
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development
December 15, 2023
These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better.
Via
InvestorPlace
Stock Market Rally Surges To 2023 Highs As Fed Pivots Toward Rate Cuts: Weekly Review
December 15, 2023
The Dow hit a record high while the S&P 500 and Nasdaq set 2023 bests.
Via
Investor's Business Daily
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
December 15, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
3 Small-Cap Stocks That Could Skyrocket 1000% by 2030
December 14, 2023
With the iShares Russell 2000 ETF (NYSE:IWM) on the move, investors should consider these small-cap stocks to buy.
Via
InvestorPlace
Topics
ETFs
3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024
December 13, 2023
These biotech stocks with promising pipelines are showing some major promise and growth potential for the new year.
Via
InvestorPlace
Why Despegar.com Shares Are Trading Higher By Over 16%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
December 13, 2023
Shares of Despegar.com, Corp. (NYSE: DESP) rose sharply during Wednesday’s session after the company raised its FY23 financial guidance. The company said it now sees revenue of $690 million to $700...
Via
Benzinga
Stocks Hold Steady, Yields Decline As Fed Meeting Looms: What's Driving Markets Wednesday?
December 13, 2023
Midway through the trading day on Wall Street, calm reigns supreme as investors eagerly await the Federal Reserve’s decision on interest rates.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
51
52
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.